主页 / 资源 / 按需随选的网络研讨会 / PBPK 模型在预测 DDI 和吸烟的影响和器官损害方面的战略性应用
PBPK 模型在预测 DDI 和吸烟的影响和器官损害方面的战略性应用
2022 年 1 月 26 日
按需随选的网络研讨会

Olanzapine is a highly effective antipsychotic, but its uses are limited by the risk of significant weight gain Olanzapine is a highly effective antipsychotic, but its uses are limited by the risk of significant weight gain and metabolic effects. A combination of olanzapine and the opioid receptor antagonist samidorphan (OLZ/SAM) was recently approved in the United States for the treatment of adults with schizophrenia and bipolar I disorder. OLZ/SAM provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain through opioid-receptor blockade. Physiologically-based pharmacokinetic (PBPK) modeling was used to assess the drug-drug interaction (DDI) potential of OLZ/SAM as well as to inform dosing in special populations, including smokers and those with organ impairment. The focus of the presentation was on leveraging PBPK modeling during the development of OLZ/SAM and regulatory interactions.

返回顶部
Powered by Translations.com GlobalLink OneLink Software